Many strategies exist to activate the GCN2-dependent branch of the ISR,16 but halo has attracted particular interest in oncology for its cancer-killing effects across multiple cancer models, which is currently in evaluation in clinical trials.17 This evidence concerns the gene EIF2AK4 and cancer.